Leukemia Clinical Trials: Active Studies & Updates
Explore active leukemia clinical trials across all major types including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Find recruiting studies, learn about eligibility criteria, and discover how clinical trials are advancing leukemia treatment.
Understanding Leukemia Clinical Trials
Clinical trials are research studies that test new treatments, procedures, or devices in people. For leukemia patients, clinical trials offer access to cutting-edge therapies that may not be available through standard treatment options.
Leukemia clinical trials test various approaches including new drugs, immunotherapy, targeted therapy, stem cell transplantation improvements, and precision medicine strategies. These trials are essential for advancing treatment and finding better approaches to leukemia care.
Types of Clinical Trials
- I Phase I Trials: Test safety and dosage of new treatments in small groups
- II Phase II Trials: Evaluate effectiveness and further assess safety
- III Phase III Trials: Compare new treatments to standard care in larger groups
- IV Phase IV Trials: Monitor long-term effects after treatment approval
Benefits of Participating
- Access to cutting-edge treatments not yet widely available
- Close monitoring and expert medical care
- Contributing to research that helps future patients
- Potential for improved outcomes compared to standard treatment
- Comprehensive follow-up and long-term care
Currently Recruiting Leukemia Clinical Trials
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.
Principal Investigator: Dr. Shai Shimony
Institution: Dana-Farber Cancer Institute
Location
Boston, Massachusetts
Timeline
Start: January 2024
Completion: December 2027
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.
Principal Investigator: Dr. Tae Kon Kim
Institution: Memorial Sloan Kettering Cancer Center
Location
New York, New York
Timeline
Start: January 2023
Completion: December 2026
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.
Principal Investigator: Dr. Madelyn Burkart
Institution: Lurie Children's Hospital
Location
Chicago, Illinois
Timeline
Start: January 2023
Completion: December 2026
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Principal Investigator: Dr. William G Wierda
Institution: City of Hope Comprehensive Cancer Center
Location
Duarte, California
Timeline
Start: January 2021
Completion: December 2024
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.
Principal Investigator: Dr. Aksinija A Kogan
Institution: Johns Hopkins Kimmel Cancer Center
Location
Baltimore, Maryland
Timeline
Start: January 2021
Completion: December 2024
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.
Principal Investigator: Dr. Matthew T Witkowski
Institution: UCSF Helen Diller Family Comprehensive Cancer Center
Location
San Francisco, California
Timeline
Start: January 2021
Completion: December 2024
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Principal Investigator: Dr. Vinod A Pullarkat
Institution: City of Hope Comprehensive Cancer Center
Location
Duarte, California
Timeline
Start: January 2020
Completion: December 2023
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Principal Investigator: Dr. Matthew Mei
Institution: City of Hope Comprehensive Cancer Center
Location
Duarte, California
Timeline
Start: January 2019
Completion: December 2022
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.
Principal Investigator: Dr. David A Jacobsohn
Institution: Lurie Children's Hospital
Location
Chicago, Illinois
Timeline
Start: January 2017
Completion: December 2020
How to Participate in Leukemia Clinical Trials
Discuss with Your Medical Team
Talk to your hematologist-oncologist about whether clinical trials might be appropriate for your situation. They can help assess eligibility and identify relevant studies.
Research Available Trials
Use resources like ClinicalTrials.gov or work with your medical team to identify trials for which you might be eligible. Consider factors like location, eligibility criteria, and trial phase.
Contact Trial Coordinators
Reach out to the research team conducting the trial. They can provide detailed information about eligibility, procedures, risks, and benefits.
Undergo Screening
If you meet initial criteria, you'll undergo comprehensive screening including medical tests, health history review, and eligibility assessment.
Find More Clinical Trials
Explore additional resources for finding leukemia clinical trials: